Lyell Immunopharma Long Term Debt 2020-2025 | LYEL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Lyell Immunopharma long term debt from 2020 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Lyell Immunopharma long term debt from 2020 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.7B
Zoetis (ZTS)	$66.3B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$43.3B
BeOne Medicines - (ONC)	$32.9B
Sandoz Group AG (SDZNY)	$25.9B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.3B
Neurocrine Biosciences (NBIX)	$13.5B
United Therapeutics (UTHR)	$12.7B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.6B
Grifols, S.A (GRFS)	$7.5B
Corcept Therapeutics (CORT)	$7.4B
Ionis Pharmaceuticals (IONS)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B